Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Amgen reports that combining Imdelltra with Imfinzi reduces the risk of death by 58% for patients with first-line extensive stage small cell lung cancer.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Amgen has announced the results of a clinical trial involving a combination drug therapy designed to treat patients suffering from aggressive lung cancer. Specifically, the company reported that using Imdelltra in combination with Imfinzi reduced the risk of death by 58% in patients with first-line extensive stage small cell lung cancer. According to the company, this reduction in the risk of death is unprecedented for this specific patient population. The therapy targets a deadly form of the disease, aiming to extend survival rates through a combined approach of targeted treatment and immunotherapy. Coverage of this development is widespread across financial and medical news outlets.
Bloomberg.com reports that the duo of drugs from Amgen and Astra boosts survival for this deadly cancer, while CNBC and Quartz both focus on the specific 58% reduction in death risk. Reuters highlights that the combination of the Amgen drug with immunotherapy successfully extends survival in the trial. Fierce Pharma describes the results presented at ESMO as a watershed moment for small cell lung cancer, noting that Imdelltra is the driver behind the massive survival benefit observed in the study. The context of this announcement is framed by the aggressive nature of small cell lung cancer, which is often difficult to treat in its extensive stage. NBC News describes the new immunotherapy combination as practice-changing, suggesting that the results could shift the standard of care for these patients.
By integrating Imdelltra with Imfinzi, the treatment seeks to address a critical need for more effective first-line therapies in oncology. The focus on first-line treatment indicates that this combo is intended for patients who have not yet received prior therapies for their extensive stage condition. Future attention will likely focus on the implementation of this combination therapy in clinical settings. Following the announcement from Amgen and the reporting from outlets like Fierce Pharma regarding the ESMO presentation, the medical community will be observing how this unprecedented survival benefit translates into broader practice. Coverage does not yet specify the timeline for regulatory approvals or the specific availability of the Imdelltra and Imfinzi combination across different global markets, though the trial data has established the primary survival metric.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21d ago.
Quick answers
What is the reported reduction in death risk?
Amgen states that the combination of Imdelltra and Imfinzi reduced the risk of death by 58%.
Which specific type of cancer was targeted in the trial?
The trial focused on patients with first-line extensive stage small cell lung cancer.
What drugs make up the combination therapy?
The combination consists of Imdelltra and Imfinzi.
Coverage (7)
- Amgen's cancer drug combo cut death risk by 58% in lung cancer trial Quartz · 24d ago
- Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer Bloomberg.com · 24d ago
- Amgen drug combined with immunotherapy extends survival in lung cancer trial Reuters · 24d ago
- ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer Fierce Pharma · 24d ago
- ‘Practice-changing’ new lung cancer immunotherapy improves survival NBC News · 24d ago
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen · 24d ago
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer CNBC · 24d ago
Topics
Related trends
Beyond statins, one drug lowered heart attack risk by 20%
Amgen's Repatha demonstrates a lower risk of heart attacks compared to ezetimibe in a large real-world study.
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche's new lung-cancer drug divarasib shows superior survival rates compared to rivals in late-stage trials, targeting the emerging oncology market.
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is showcasing a new portfolio of targeted cancer therapies, featuring a stomach cancer drug that significantly extended patient survival times.
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
U.S. stocks tumble as crude oil approaches $100 per barrel and inflation data approaches.